Stryker Corporation (NYSE:SYK) received a $156.00 target price from analysts at Oppenheimer Holdings, Inc. in a report released on Monday. The brokerage presently has a “hold” rating on the medical technology company’s stock. Oppenheimer Holdings, Inc.’s price objective would indicate a potential upside of 0.41% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Wells Fargo & Company raised their price target on shares of Stryker Corporation from $160.00 to $166.00 in a research note on Friday. Cowen and Company reissued a “buy” rating and issued a $160.00 price target (up from $150.00) on shares of Stryker Corporation in a research note on Sunday, July 30th. Stifel Nicolaus raised their price target on shares of Stryker Corporation from $151.00 to $158.00 and gave the stock a “buy” rating in a research note on Friday, July 28th. Zacks Investment Research raised shares of Stryker Corporation from a “hold” rating to a “buy” rating and set a $163.00 price target on the stock in a research note on Monday, July 17th. Finally, BidaskClub raised shares of Stryker Corporation from a “hold” rating to a “buy” rating in a research note on Thursday, August 17th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $151.52.

Stryker Corporation (NYSE SYK) opened at 155.37 on Monday. Stryker Corporation has a one year low of $106.48 and a one year high of $160.62. The company has a 50-day moving average of $145.94 and a 200 day moving average of $142.17. The company has a market cap of $58.12 billion, a P/E ratio of 34.68 and a beta of 0.81.

Stryker Corporation (NYSE:SYK) last announced its earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. Stryker Corporation had a net margin of 14.67% and a return on equity of 24.11%. The business had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.97 billion. During the same quarter last year, the business earned $1.39 earnings per share. The company’s revenue for the quarter was up 6.1% compared to the same quarter last year. Analysts anticipate that Stryker Corporation will post $6.44 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Stryker Corporation (SYK) Given a $156.00 Price Target by Oppenheimer Holdings, Inc. Analysts” was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://theolympiareport.com/2017/10/31/stryker-corporation-syk-given-a-156-00-price-target-by-oppenheimer-holdings-inc-analysts.html.

In other Stryker Corporation news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the transaction, the insider now owns 88,207 shares in the company, valued at approximately $12,909,976.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Graham A. Mclean sold 1,124 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total transaction of $164,396.24. Following the transaction, the insider now owns 8,983 shares of the company’s stock, valued at approximately $1,313,853.58. The disclosure for this sale can be found here. Insiders own 7.40% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Acrospire Investment Management LLC acquired a new position in shares of Stryker Corporation in the 2nd quarter valued at $111,000. Motco boosted its holdings in shares of Stryker Corporation by 50.7% in the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock valued at $115,000 after buying an additional 278 shares in the last quarter. Bollard Group LLC boosted its holdings in shares of Stryker Corporation by 0.4% in the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock valued at $115,000 after buying an additional 3 shares in the last quarter. Bruderman Asset Management LLC acquired a new position in shares of Stryker Corporation in the 2nd quarter valued at $150,000. Finally, James Investment Research Inc. acquired a new position in shares of Stryker Corporation in the 2nd quarter valued at $155,000. Institutional investors and hedge funds own 74.00% of the company’s stock.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.